The 2017 Update of the Standard of Care Recommendations for Spinal Muscular Atrophy
This webcast is based on a discussion between two leading experts in the field of spinal muscular atrophy (SMA) who exchange views on “The 2017 Update of the Standard of Care Recommendations for SMA”. They summarize and review the current best practices for diagnosis, multidisciplinary care, physical therapy, orthopedic care, nutrition, pulmonary care, and acute care and discuss how novel treatment options such as newly approved medications have impacted the outlook for patients and are changing the care setting. The experts provide an outlook on how developments such as newborn screening will influence the future of SMA management.
This activity has been designed to meet the educational needs of a broad audience including neurologists, pediatricians, pulmonologists, physical therapists, orthopedists, and other HCPs responsible for the diagnosis, treatment, or management of patients with SMA.
After viewing this activity, participants will be better able to:
- Implement the currently recommended algorithm for SMA diagnosis in daily clinical practice
- Apply a multidisciplinary approach to the management of SMA according to the current best practices
- Develop a comprehensive care plan in close cooperation with neurologists, physical therapists, respiratory therapists, and other members of the multidisciplinary team
- Describe the key benefits of the first treatment approved for the management of SMA
|Richard Finkel, MD|
Nemours Children’s Hospital
Orlando, FL, USA
Thomas Crawford, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this Continuing Medical Education (CME) activity:
|Faculty||Relationship Identified With:|
|Richard Finkel, MD|
Consultant/Advisor: AveXis, Inc., Biogen, F. Hoffman-La Roche Ltd, Ionis PharmaceuticalsTM, Novartis AGGrant/Research Support: AveXis, Inc., Biogen, Cytokinetics, Inc., F. Hoffman-La Roche Ltd, Ionis PharmaceuticalsTM
|Thomas Crawford, MD||Consultant/Advisor: Aventis Pharmaceuticals Inc. and Biogen|
Non-faculty: Sandy Breslow; Alison Kemp; Bernie M. Abrams, MD; Cordelia Nagle; Elena Knoche, PhD; Marijke Verhaaf; hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Biogen.
Jointly provided by the Elsevier Office of Continuing Medical Education and Excerpta Medica.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Excerpta Medica. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Credits (Nursing)
In support of improving patient care, this activity has been planned and implemented by Dannemiller and Elsevier Office of Continuing Medical Education. Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Dannemiller designates this educational activity for 1.0 contact hours.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Excerpta Medica and Biogen do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Nursing Contact Hours
- 1.00 Non-physician